Cornea/External Disease News

Mucormycosis is an opportunistic fungal infection that manifests in patients with low immunity. Although the fungus spores are ubiquitous in nature and found in the environment, fungal infections rarely occur in immunocompetent individuals.

We know from twin and familial studies that keratoconus has a genetic component. First-degree relatives of people with keratoconus have a 15- to 67-fold greater risk for keratoconus than the general population.

Study results from a promising dry eye disease candidate and a blog about corneal cross-linking are two of the best-performing cornea/external disease items from September.

NOV03 met all primary and secondary sign and symptom endpoints in a second phase 3 trial investigating the therapy for dry eye disease treatment, according to a press release from Bausch + Lomb and Novaliq.

NCX 4251 did not meet the primary or secondary efficacy endpoints in a phase 2b clinical trial investigating the ophthalmic suspension in patients with acute exacerbations of blepharitis, according to a press release from Nicox.

Sigh. Summertime in the northern latitudes is a fleeting joy.

A speaker at the Real World Ophthalmology meeting offered advice on how to be successful after finishing a cornea fellowship and beginning a career in practice.Nadia Haqqie, MD, said being a young physician can be difficult. Colleagues may send fairly complex cases, and it is not always easy to have all the answers right away.

Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites, according to a press release.

As a cornea specialist, I have no doubt about the clinical value of cross-linking.

AR-15512 achieved statistical significance for multiple sign and symptom endpoints in patients with dry eye disease, according to a press release from Aerie Pharmaceuticals.